BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) DNA dynamics during long-term antiretroviral therapy (ART) are not defined. METHODS: Blood mononuclear cells obtained during 7-12 years of effective ART were assayed for total HIV-1 DNA and 2-long terminal repeat (LTR) circles by quantitative polymerase chain reaction (qPCR). Slopes of HIV-1 DNA were estimated by participant-specific linear regressions. Plasma was assayed for residual viremia (HIV-1 RNA) by qPCR. RESULTS: Thirty participants were studied. HIV-1 DNA decreased significantly from years 0-1 and 1-4 of ART with median decay slopes of -0.86 (interquartile range, -1.05, -0.59) and -0.11 (-0.17, -0.06) log10(copies/10(6) CD4+ T-cells)/year, respectively (P < .001). Decay was not significant for years 4-7 (-0.02 [-0.06, 0.02]; P = .09) or after year 7 of ART (-0.006 [-0.030, 0.015]; P = .17). All participants had detectable HIV-1 DNA after 10 years (median 439 copies/10(6) CD4+ T-cells; range: 7-2074). Pre-ART HIV-1 DNA levels were positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, P < .001) and with HIV-1 DNA at years 4, 7, and 10 on ART (Spearman ≥ 0.75, P < .001). No associations were found (P ≥ .25) between HIV-1 DNA slopes or levels and % activated CD8+ T-cells (average during years 1-4) or residual viremia (n = 18). 2-LTR circles were detected pre-ART in 20/29 and in 8/30 participants at last follow-up. CONCLUSIONS: Decay of HIV-1 DNA in blood is rapid in the first year after ART initiation (86% decline), slows during years 1-4 (23% decline/year), and subsequently plateaus. HIV-1 DNA decay is not associated with the levels of CD8+ T-cell activation or persistent viremia. The determinants of stable HIV-1 DNA persistence require further elucidation. Clinical Trials Registration. NCT00001137.
BACKGROUND:Human immunodeficiency virus type 1 (HIV-1) DNA dynamics during long-term antiretroviral therapy (ART) are not defined. METHODS: Blood mononuclear cells obtained during 7-12 years of effective ART were assayed for total HIV-1 DNA and 2-long terminal repeat (LTR) circles by quantitative polymerase chain reaction (qPCR). Slopes of HIV-1 DNA were estimated by participant-specific linear regressions. Plasma was assayed for residual viremia (HIV-1 RNA) by qPCR. RESULTS: Thirty participants were studied. HIV-1 DNA decreased significantly from years 0-1 and 1-4 of ART with median decay slopes of -0.86 (interquartile range, -1.05, -0.59) and -0.11 (-0.17, -0.06) log10(copies/10(6) CD4+ T-cells)/year, respectively (P < .001). Decay was not significant for years 4-7 (-0.02 [-0.06, 0.02]; P = .09) or after year 7 of ART (-0.006 [-0.030, 0.015]; P = .17). All participants had detectable HIV-1 DNA after 10 years (median 439 copies/10(6) CD4+ T-cells; range: 7-2074). Pre-ART HIV-1 DNA levels were positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, P < .001) and with HIV-1 DNA at years 4, 7, and 10 on ART (Spearman ≥ 0.75, P < .001). No associations were found (P ≥ .25) between HIV-1 DNA slopes or levels and % activated CD8+ T-cells (average during years 1-4) or residual viremia (n = 18). 2-LTR circles were detected pre-ART in 20/29 and in 8/30 participants at last follow-up. CONCLUSIONS: Decay of HIV-1 DNA in blood is rapid in the first year after ART initiation (86% decline), slows during years 1-4 (23% decline/year), and subsequently plateaus. HIV-1 DNA decay is not associated with the levels of CD8+ T-cell activation or persistent viremia. The determinants of stable HIV-1 DNA persistence require further elucidation. Clinical Trials Registration. NCT00001137.
Authors: Kersten K Koelsch; Lin Liu; Richard Haubrich; Susanne May; Diane Havlir; Huldrych F Günthard; Caroline C Ignacio; Paula Campos-Soto; Susan J Little; Robert Shafer; Gregory K Robbins; Richard T D'Aquila; Yuji Kawano; Karen Young; Phillip Dao; Celsa A Spina; Douglas D Richman; Joseph K Wong Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson Journal: HIV Clin Trials Date: 2008 Jul-Aug
Authors: Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado Journal: Nat Med Date: 2010-03-14 Impact factor: 53.440
Authors: D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli Journal: Clin Infect Dis Date: 2010-03-15 Impact factor: 9.079
Authors: J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli Journal: Proc Natl Acad Sci U S A Date: 2009-05-22 Impact factor: 11.205
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: Thomas W North; Joanne Higgins; Jesse D Deere; Timothy L Hayes; Andradi Villalobos; Lourdes Adamson; Barbara L Shacklett; Raymond F Schinazi; Paul A Luciw Journal: J Virol Date: 2009-12-23 Impact factor: 5.103
Authors: Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron Journal: PLoS Med Date: 2010-08-10 Impact factor: 11.069
Authors: Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li Journal: J Virol Date: 2015-11-18 Impact factor: 5.103
Authors: Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho Journal: Cell Host Microbe Date: 2017-04-12 Impact factor: 21.023
Authors: Graham C Treasure; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael Para; Rajesh T Gandhi; Jonathan Z Li Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Francesco Marras; Anna Casabianca; Federica Bozzano; Maria Libera Ascierto; Chiara Orlandi; Antonio Di Biagio; Emanuele Pontali; Chiara Dentone; Giancarlo Orofino; Laura Nicolini; Lucia Taramasso; Mauro Magnani; Francesco M Marincola; Ena Wang; Lorenzo Moretta; Andrea De Maria Journal: J Virol Date: 2017-11-14 Impact factor: 5.103
Authors: Mary F Kearney; Ann Wiegand; Wei Shao; William R McManus; Michael J Bale; Brian Luke; Frank Maldarelli; John W Mellors; John M Coffin Journal: Open Forum Infect Dis Date: 2017-09-19 Impact factor: 3.835
Authors: Shane D Falcinelli; Bonnie E Shook-Sa; Morgan G Dewey; Sumati Sridhar; Jenna Read; Jennifer Kirchherr; Katherine S James; Brigitte Allard; Simon Ghofrani; Erin Stuelke; Caroline Baker; Nadia R Roan; Joseph J Eron; JoAnn D Kuruc; Catalina Ramirez; Cynthia Gay; Katie R Mollan; David M Margolis; Adaora A Adimora; Nancie M Archin Journal: J Infect Dis Date: 2020-11-09 Impact factor: 5.226